Illumina, Inc. (ILMN) has received approval from Japan’s Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). As genomic insights continue to drive breakthroughs in cancer treatment, the test is designed to make precision oncology more accessible to oncologists and patients.The latest development bolsters the company’s oncology portfolio. Illumina also stated that its clinical oncology offerings will be feat ...